S2209: A PHASE III RANDOMIZED TRIAL FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS CONSIDERED FRAIL OR IN A SUBSET OF INTERMEDIATE FIT COMPARING UPFRONT THREE-DRUG INDUCTION REGIMENS FOLLOWED BY DOUBLE- OR SINGLE-AGENT MAINTENANCE.

16630S2209-NCT05561387OpenS2209: A PHASE III RANDOMIZED TRIAL FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS CONSIDERED FRAIL OR IN A SUBSET OF INTERMEDIATE FIT COMPARING UPFRONT THREE-DRUG INDUCTION REGIMENS FOLLOWED BY DOUBLE- OR SINGLE-AGENT MAINTENANCE.S2209NCT05561387NationalAdultTreatmentIIIGlobalMultiple MyelomaShenoy, AarthiMedStar Health and GUMC; Medstar Washington Hospital CenterMultiple MyelomaOncology GroupMHRI Washington Cancer Institute2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>